Inhibrx Biosciences, Inc.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.3M
- Net income
- -$140.1M
- Total assets
- $146.5M
- Market cap
- $1.3B
- Operating margin
- -10386.5%
- Net margin
- -10773.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.3M
- Operating expenses
- $136.3M
- Operating income
- -$135.0M
- Income tax
- $2.0K
- Net income
- -$140.1M
- EPS (basic)
- $-9.04
- EPS (diluted)
- $-9.04
Balance sheet
- Total assets
- $146.5M
- Current assets
- $132.8M
- Total liabilities
- $138.5M
- Current liabilities
- $33.8M
- Shareholders’ equity
- $8.0M
Cash flow
- Operating cash flow
- -$129.8M
- Investing cash flow
- -$28.0K
- Financing cash flow
- $101.4M
- Net cash flow
- -$28.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-9.04
- Shares outstanding
- 14.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 28, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $140.1M in FY2025.
- Revenue declined 82% from FY2021 to FY2025.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Inhibrx Biosciences, Inc..
Write a review
News about Inhibrx Biosciences, Inc.
News & sentiment via Polygon.io
